Loading…
Neuphoria Therapeutics Inc. is projected to rise to $6.02 by 2027, a +11% move from its current price of $5.40. NEUP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.24 | $5.40 | $5.57 | +0.02% |
| May 30 | $5.18 | $5.40 | $5.64 | +0.03% |
| May 31 | $5.13 | $5.40 | $5.69 | +0.05% |
| Jun 1 | $5.09 | $5.40 | $5.74 | +0.06% |
| Jun 2 | $5.05 | $5.40 | $5.78 | +0.08% |
| Jun 3 | $5.02 | $5.41 | $5.82 | +0.09% |
| Jun 4 | $4.99 | $5.41 | $5.85 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.99 | $5.41 | $5.85 | +0.11% |
| Week 2 | $4.83 | $5.41 | $6.06 | +0.22% |
| Week 3 | $4.72 | $5.42 | $6.22 | +0.33% |
| Week 4 | $4.62 | $5.42 | $6.36 | +0.44% |
| Week 5 | $4.54 | $5.43 | $6.49 | +0.55% |
| Week 6 | $4.47 | $5.44 | $6.61 | +0.66% |
| Week 7 | $4.41 | $5.44 | $6.72 | +0.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neuphoria Therapeutics Inc. is a clinical stage biopharmaceutical company that discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate is BNC210, a selective negative allosteric modulator of the a7 receptor for social anxiety disorder and is in phase 2b to treat post-traumatic stress disorder.
The company also develops BNC101, a monoclonal antibody that targets cancer stem cells, and BNC105 for the treatment of cancer. It is advancing NextGen in preclinical trial for the treatment of multiple central nervous system indications, and Kv3.1/3.2 agonist in preclinical trial to address potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. Neuphoria Therapeutics has a collaboration with Merck & Co., Inc.
to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024.
Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Neuphoria Therapeutics Inc. (NEUP) currently trades at $5.48, with a market capitalization of $29.62M and a rank of 4810. The current price sits within a forecasted path that projects gradual upside over time, with year-by-year targets through 2050 highlighted by the following milestones: 2026 avg $5.48 (min $3.82, max $6.99, ROI 0%), 2027 avg $6.27 (min $4.91, max $8.51, ROI 14.3%), 2028 avg $6.95 (min $5.28, max $9.81, ROI 26.8%), 2029 avg $8.86 (min $6.56, max $12.89, ROI 61.6%), 2030 avg $10.69 (min $7.74, max $15.98, ROI 95.1%), 2031 avg $11.42 (min $8.09, max $17.46, ROI 108.4%), 2032 avg $11.83 (min $8.22, max $18.46, ROI 115.8%), 2033 avg $11.83 (min $8.07, max $18.80, ROI 115.8%), 2034 avg $13.47 (min $9.02, max $21.78, ROI 145.7%), 2035 avg $16.49 (min $10.86, max $27.09, ROI 200.9%), 2040 avg $22.80 (min $13.90, max $40.03, ROI 316.1%), 2050 avg $50.98 (min $27.12, max $98.54, ROI 830.4%).
The forecast also shows a generally bullish sentiment toward the longer term.
A major floor 27.0% below — a decisive break under it would weaken the trend.
The nearest floor, 13.9% below — buyers have tended to step in here.
Price is pressing into resistance (1.5% away) — a breakout level to watch.
A major ceiling 11.2% above — clearing it would confirm fresh momentum.
Key NEUP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NEUP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.28 | Buy | $5.29 | Buy |
| MA 10 | $5.07 | Buy | $5.19 | Buy |
| MA 20 | $5.16 | Buy | $5.11 | Buy |
| MA 50 | $4.83 | Buy | $4.91 | Buy |
| MA 100 | $4.51 | Buy | $4.99 | Buy |
| MA 200 | $6.42 | Sell | $5.58 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.21 | Neutral |
| Stoch RSI (14) | 77.98 | Neutral |
| CCI (20) | 80.35 | Neutral |
| Williams %R (14) | -10.53 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 1.69 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 89.47 | Sell |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | 0.24 | Buy |
| Ultimate (7,14,28) | 74.28 | Sell |
| Momentum (10) | 0.47 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 5.56 | Sell |
| ADX (14) | 19.61 | Neutral |
| ATR (14) | 0.12 | Info |
The near-term technical picture is bullish. RSI(14) is 60, consistent with constructive momentum.
The stock is trading with a mix of moving averages: SMA50 is $4.79 and SMA200 is $6.44, framing near-term support and resistance levels. The current structure places a resistance at $5.48 and a support at $4.57, framing a narrow trading corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.82 | $5.40 | $6.86 | 0% | Neutral | |
| $4.73 | $6.02 | $8.15 | +11% | Neutral | |
| $5.02 | $6.59 | $9.28 | +22% | Bullish | |
| $6.19 | $8.34 | $12.11 | +54% | Bullish | |
| $7.20 | $9.92 | $14.78 | +84% | Bullish | |
| $7.57 | $10.64 | $16.21 | +97% | Bullish | |
| $7.70 | $11.04 | $17.16 | +104% | Bullish | |
| $7.40 | $10.80 | $17.11 | +100% | Bullish | |
| $8.25 | $12.26 | $19.74 | +127% | Bullish | |
| $9.86 | $14.90 | $24.38 | +176% | Bullish | |
| $12.52 | $20.42 | $35.67 | +278% | Bullish | |
| $24.10 | $44.92 | $86.34 | +732% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.82 | $5.40 | $6.33 | +0.00% |
| June 2026 | $4.54 | $5.35 | $6.45 | -0.97% |
| July 2026 | $4.61 | $5.48 | $6.71 | +2.44% |
| August 2026 | $4.50 | $5.39 | $6.68 | -1.62% |
| September 2026 | $4.32 | $5.20 | $6.50 | -3.48% |
| October 2026 | $4.38 | $5.30 | $6.69 | +1.98% |
| November 2026 | $4.49 | $5.47 | $6.94 | +3.04% |
| December 2026 | $4.39 | $5.37 | $6.86 | -1.82% |
Click any year to see its month-by-month NEUP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Neuphoria Therapeutics Inc.'s 2026 outlook centres on $5.40, within a $3.82 to $6.86 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, NEUP could reach as high as $8.15, with a base case around $6.02 and support toward $4.73 — roughly +11% from $5.40. Price action looks broadly range-bound.
Expect NEUP to range from $5.02 to $9.28 through 2028. The $6.59 average target implies a +22% move from current prices. That is up +10% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The NEUP price prediction for 2029 points to an average of $8.34 (low $6.19, high $12.11) — a potential gain of +54% on today's $5.40. Momentum favours further upside here.
In 2030, NEUP is projected to trade between $7.20 and $14.78, averaging $9.92 — a potential gain of +84% from today's $5.40. That is up +19% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Neuphoria Therapeutics Inc.'s 2031 outlook centres on $10.64, within a $7.57 to $16.21 range. That is up +7% on the projected 2030 average. That marks a +97% change versus current levels. Momentum favours further upside here.
By 2032, NEUP could reach as high as $17.16, with a base case around $11.04 and support toward $7.70 — roughly +104% from $5.40. Buyers look set to stay in control over this stretch.
Expect NEUP to range from $7.40 to $17.11 through 2033. The $10.80 average target implies a +100% move from current prices. That is -2% versus the projected 2032 average. Momentum favours further upside here.
The NEUP price prediction for 2034 points to an average of $12.26 (low $8.25, high $19.74) — a potential gain of +127% on today's $5.40. Buyers look set to stay in control over this stretch.
In 2035, NEUP is projected to trade between $9.86 and $24.38, averaging $14.90 — a potential gain of +176% from today's $5.40. That is up +22% on the projected 2034 average. Momentum favours further upside here.
Neuphoria Therapeutics Inc.'s 2040 outlook centres on $20.42, within a $12.52 to $35.67 range. That is up +37% on the projected 2035 average. That marks a +278% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, NEUP could reach as high as $86.34, with a base case around $44.92 and support toward $24.10 — roughly +732% from $5.40. Momentum favours further upside here.
Investing $1,000 in NEUP today (≈ 185.185185 NEUP) could be worth
$8,318.76
+$7,318.76 (+732%) by 2050 · US Dollar
Based on the average projected NEUP price of $44.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NEUPwould be worth at today's price.
$1,000 invested in NEUP on May 27, 2025 (≈ 148.367958 NEUP) would be worth
$801.19
-$198.81 (-19.9%) today · 0.80× · US Dollar
Based on a NEUP entry price of $6.74 vs. today's $5.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.93 | $1,095.33 | +9.5% |
| 1 month ago | $5.15 | $1,048.54 | +4.9% |
| 3 months ago | $4.36 | $1,238.53 | +23.9% |
| 6 months ago | $4.52 | $1,194.69 | +19.5% |
| 1 year ago | $6.74 | $801.19 | -19.9% |
| All time (4.4y) ago | $176.76 | $30.55 | -96.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NEUP forecast.
Our base-case forecast reaches $11.00 around 2032.
Implied market cap at $11.00: $59.45M
The multi-year outlook shows meaningful upside across multiple milestones. By 2030 the average target is $10.69, with a max of $15.98 and a min of $7.74, reflecting a 95.1% potential ROI in the year. By 2040 the average target rises to $22.80, with a max of $40.03 and a min of $13.90, corresponding to a 316.1% ROI.
By 2050 the average target is $50.98, with a max of $98.54 and a min of $27.12, implying an 830.4% ROI.
The forecast indicates neutral sentiment for 2026 (avg $5.48, ROI 0%) and 2027 (avg $6.27, ROI 14.3%), followed by bullish sentiment from 2028 onward (avg rising to $6.95 in 2028, $8.86 in 2029, and higher in later years). These are estimates, not guarantees, and outcomes depend on factors such as clinical progress, regulatory dynamics, and market conditions.
Tap a question to reveal the answer.
The forecast shows an average price of $10.69 in 2030, with a minimum of $7.74 and a maximum of $15.98; the associated ROI is 95.1% and the sentiment is BULLISH.
Longer-term forecasts point to bullish upside, with average prices rising to $10.69 by 2030 and $50.98 by 2050, and ROIs of 95.1% in 2030 and 830.4% in 2050. Earlier years show more modest gains (e.g., 2027 avg $6.27, ROI 14.3%), and 2026 is neutral with ROI 0%. These are estimates and not guarantees.
According to the forecast, the 2050 maximum is $98.54, which does not reach $100.
Current price is $5.48 and market cap is $29.62M.
Sentiment is BULLISH with RSI(14) at 60. The 30-day range spans from $4.48 to $6.70, with SMA50 at $4.79 and SMA200 at $6.44. Support is $4.57 and resistance is $5.48.
Neuphoria Therapeutics Inc. Community Discussion
0Share your Neuphoria Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.